CD8A and neoplasm: Single-cell TCR-seq showed that both better effectors, generated following muPD1-IL2v treatment, and the exhausted T cells that arise following treatment with muPD-1 as monotherapy or in combination with muFAP-IL2v consisted of clonally expanded CD8+ TILs (Fig. 4j), a bona fide indicator of tumour specificity and productive immune response48,49.